- Home
- PIII vs BFRI Comparison
PIII vs BFRI Comparison
Compare PIII & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | BFRI |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | 360 | 93 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 10.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIII | BFRI |
|---|---|---|
| Price | $2.82 | $0.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $16.25 | $2.75 |
| AVG Volume (30 Days) | 100.9K | ★ 107.3K |
| Earning Date | 03-26-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | $14.85 | $19.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.54 |
| 52 Week High | $11.30 | $1.18 |
Technical Indicators
Market Signals| Indicator | PIII | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 52.47 | 39.81 |
| Support Level | $1.52 | $0.71 |
| Resistance Level | $2.85 | $0.89 |
| Average True Range (ATR) | 0.53 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 30.81 | 11.94 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.